Opendata, web and dolomites

BraINstorm SIGNED

Engineered nanocarriers for simultaneous anticancer immune response and “switching” of tumor-associated macrophages for intranasal glioblastoma treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BraINstorm project word cloud

Explore the words cloud of the BraINstorm project. It provides you a very rough idea of what is the project "BraINstorm" about.

macrophage    reduces    drug    performed    re    tam    oligonucleotide    appealing    taas    intranasal    generating    treat    brainstorm    parallel    microenvironment    invasiveness    ex    therapeutic    adhesivity    therapies    nasal    release    storm    tumoral    blood    macrophages    rate    m1    advantage    size    memory    followed    turning       comprise    resection    standard    regards    physical    combination    promotes    vivo    disease    infiltrated    cells    patient    glioblastoma    invasive    local    hyaluronic    model    chemical    anticancer    types    effect    muco    stimulation    immunomodulatory    barrier    50    brain    switch    intrinsic    immunoconjugates    tackle    gbm    radiotherapy    surgery    chemotherapy    mucosa    prophylactic    acid    tumor    cancer    peptides    cpg    immune    expansion    immunotherapeutic    biocompatibility    anti    conventional    conjugates    m2    education    treatment    position    engineer    preliminary    clinically    complexity    lasting    crossing    explored    strategy    explore    assessing    immunotherapy    emerged    administration    nose    precludes    vitro    care    curable    route    survival    antigen    oligonucleotides   

Project "BraINstorm" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE CATHOLIQUE DE LOUVAIN 

Organization address
address: PLACE DE L UNIVERSITE 1
city: LOUVAIN LA NEUVE
postcode: 1348
website: www.uclouvain.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 166˙320 €
 EC max contribution 166˙320 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) coordinator 166˙320.00

Map

 Project objective

Glioblastoma (GBM) remains a non-curable disease due to its high complexity and its position beyond the blood-brain barrier, which precludes access by conventional therapies. The current standard of care includes tumor resection surgery followed by radiotherapy or chemotherapy; an invasive process with a survival rate after five years is less than 5%. Tumor-associated macrophages (TAM) type 2 (M2 macrophages) comprise 30-50% of the infiltrated cells in GBM microenvironment and support tumor expansion. Immunotherapy represents an appealing strategy to treat several cancer types by turning the immune system against tumor cells; tumor antigen peptides (TAAs) recently emerged as an immunotherapeutic approach that can provide for a long-lasting immune response. Immunomodulatory oligonucleotides can “switch” M2 macrophages into M1 macrophages that produce an anti-tumoral effect. The BraINstorm (Brain INtranasal storm) project aims to engineer a hyaluronic acid (HA)-based combination conjugates that tackle GBM by the stimulation of the immune system via the delivery of TAAs and an immunomodulatory oligonucleotide (CpG) that promotes M2 macrophage “re-education” generating an “anticancer storm”. In parallel, taking advantage of the intrinsic muco-adhesivity of HA, BraINstorm will explore the nose-to-brain drug delivery, a more patient-friendly route that reduces the invasiveness. Novel combination immunoconjugates will be fully chemical-physical characterized and preliminary in vitro studies will be performed assessing the biocompatibility, drug release, and nasal mucosa barrier crossing in an ex-vivo model. Finally, the prophylactic and therapeutic activity of the HA-based conjugates will be in vivo explored in a clinically relevant GBM in vivo model through intranasal (IN) and local treatment administration with regards to effects on tumor size, immune memory, and survival.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINSTORM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRAINSTORM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MathematicsAnalogies (2019)

Mathematics Analogies

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More  

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  
relatedResult rcn (858517) AGGIORNATO correttamente
lastchecktime (2022-08-18 2:01:11) correctly updated